tiprankstipranks
Advertisement
Advertisement
4BIO Capital Portfolio Company Ray Therapeutics Secures $125 Million Series B for Optogenetic Programs
PremiumPrivate Companies4BIO Capital Portfolio Company Ray Therapeutics Secures $125 Million Series B for Optogenetic Programs
1M ago
Ray Therapeutics Raises $125 Million Series B to Advance Optogenetic Vision Programs
Premium
Private Companies
Ray Therapeutics Raises $125 Million Series B to Advance Optogenetic Vision Programs
1M ago
4BIO Capital Deepens Role as Founding Investor as Ray Therapeutics Secures $125 Million Series B
Premium
Private Companies
4BIO Capital Deepens Role as Founding Investor as Ray Therapeutics Secures $125 Million Series B
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100